Industry News: Mayo Clinic Provides A High-Level Look Into Glioblastoma https://ibn.fm/XflvS #braincancer #glioblastoma #neuro-oncology
CNS Pharmaceuticals, Inc.
Biotechnology Research
Houston, TX 983 followers
Pre-Clinical Stage Biotech Company Focused on Developing Novel Treatments for Brain Tumors
About us
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, please visit www.cnspharma.com.
- Website
-
http://www.cnspharma.com
External link for CNS Pharmaceuticals, Inc.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Houston, TX
- Type
- Public Company
- Founded
- 2017
- Specialties
- Biotechnology, Pharmaceuticals, and Healthcare
Locations
-
Primary
Houston, TX 77027, US
Employees at CNS Pharmaceuticals, Inc.
Updates
-
Industry News: Exploring Fetal Brain Tumor Glioblastoma Symptom Verification With Self Organizing Maps And Vulnerability Data Analysis (Report) https://ibn.fm/URd1L #braincancer #glioblastoma #neuro-oncology
Exploring fetal brain tumor glioblastoma symptom verification with self organizing maps and vulnerability data analysis - Scientific Reports
nature.com
-
Industry News: Artificial Intelligence In Neuro-Oncology: Advances And Challenges In Brain Tumor Diagnosis, Prognosis, And Precision Treatment https://ibn.fm/tt4NT #braincancer #glioblastoma #neuro-oncology
Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment - npj Precision Oncology
nature.com
-
We will be attending the LSX World Congress happening April 29-30 in London! We look forward to a productive time with industry peers. #GlioblastomaMultiforme #GBM #Oncology
-
Industry News: Preliminary Clinical Trial Results Show ‘Dramatic and Rapid’ Regression of Glioblastoma after Next Generation CAR-T Therapy https://ibn.fm/P5ouO #braincancer #glioblastoma #neuro-oncology
Preliminary Clinical Trial Results Show ‘Dramatic and Rapid' Regression of Glioblastoma after Next Generation CAR-T Therapy
massgeneral.org
-
Grab your lunch and join us today at 12 PM ET for the Virtual Investor Lunch Break: The CNSP Opportunity! Register here: https://bit.ly/44efENZ #GlioblastomaMultiforme #GBM #Oncology
-
CNS Pharmaceuticals to Present at the LSX World Congress 2024 https://bit.ly/3vVlabL #GBM #GlioblastomeMultiforme #Oncology
CNS Pharmaceuticals to Present at the LSX World Congress 2024
-
Industry News: New Studies Suggest Scientists Are Finally Figuring Out How To Harness The Immune System To Attack A Ruthless Form Of Brain Cancer https://ibn.fm/bXVgv #braincancer #glioblastoma #neuro-oncology
This brain cancer breakthrough should excite you
-
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity https://bit.ly/4d9SjRs #GBM #GlioblastomaMultiforme #Oncology
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
https://cnspharma.com